Gene-Edited immune cells take on Hard-to-Treat cancers
NCT ID NCT05795595
First seen Jan 09, 2026 · Last updated May 12, 2026 · Updated 18 times
Summary
This early-phase trial tested a new treatment called CTX131 for adults with several types of advanced solid tumors that had stopped responding to standard therapies. CTX131 uses a patient's own immune cells that are edited with CRISPR technology to target a protein called CD70 on cancer cells. The study aimed to check the treatment's safety and whether it could shrink tumors, involving 19 participants with cancers like kidney, cervical, or pancreatic cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Nashville, Tennessee, 37203, United States
-
Research Site 2
St Louis, Missouri, 63110, United States
-
Research Site 3
Duarte, California, 91010, United States
-
Research Site 4
Durham, North Carolina, 27710, United States
-
Research Site 5
Houston, Texas, 77030, United States
-
Research Site 6
Boston, Massachusetts, 02215, United States
-
Research Site 7
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.